-+ 0.00%
-+ 0.00%
-+ 0.00%

Celcuity Publishes Presentation on Updated VIKTORIA-1 Study 2 Breast Cancer Results

PUBT·10/24/2026 08:21:21
Listen to the news
Celcuity Publishes Presentation on Updated VIKTORIA-1 Study 2 Breast Cancer Results
  • Celcuity published updated VIKTORIA-1 Study 2 results in PIK3CA-mutant, HR-positive/HER2-negative advanced breast cancer.
  • Gedatolisib with fulvestrant and palbociclib significantly improved progression-free survival versus alpelisib with fulvestrant, reaching a median 11.1 months (hazard ratio: 0.50).
  • Without palbociclib, gedatolisib with fulvestrant significantly improved progression-free survival versus the same comparator, reaching a median 11.3 months (hazard ratio: 0.51).
  • Adverse events associated with gedatolisib-based treatment were mainly grade 1 or 2.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celcuity Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.